Baidu
map

Eur Heart J:醛固酮在慢性肾病和肾脏结局中的作用

2022-08-10 MedSci原创 MedSci原创

慢性肾病患者血清醛固酮水平升高与肾脏疾病进展风险增加独立相关,与糖尿病无关。这些结果为MR拮抗剂延缓慢性肾病进展提供了机制证据,并提示它们可能在非糖尿病患者中也有作用。

随机对照试验已经证明了盐皮质激素受体(MR)拮抗剂能够延缓糖尿病慢性肾病进展;然而,他们还没有调查醛固酮的作用,以及这些有益的效应是否可以在没有糖尿病的个体中也能观察到。

近日,心血管领域权威杂志Eur Heart J上发表了一篇研究文章,在3680名慢性肾功能不全队列参与者中探究了血清醛固酮浓度与肾脏疾病进展之间的关系。

该研究的主要结局为慢性肾病进展[定义为估计的肾小球滤过率(eGFR)下降50%或终末期肾脏疾病(以先发生者为准)的综合结局]。研究人员使用Cox比例风险模型评估血清醛固酮与肾脏疾病预后之间的关系。

基线时,较高的醛固酮浓度与较低的表皮生长因子受体、较低的血清钾、较高的尿钾和蛋白质排泄有关。在平均9.6年的随访中,1412名参与者发生了慢性肾病进展。在调整后的模型中,血清醛固酮水平每增加一倍,慢性肾病进展风险增加11%[风险比为1.11,95%可信区间为1.04-1.18]。血清醛固酮水平最高的个体与水平最低的个体相比,慢性肾病进展风险增加45%(风险比为1.45,95%可信区间为1.22-1.73)。无论患者是否合并糖尿病,慢性肾病进展的风险是相似的(相互作用p=0.10)。

由此可见,慢性肾病患者血清醛固酮水平升高与肾脏疾病进展风险增加独立相关,与糖尿病无关。这些结果为MR拮抗剂延缓慢性肾病进展提供了机制证据,并提示它们可能在非糖尿病患者中也有作用。

原始出处:

Ashish Verma,et al.Aldosterone in chronic kidney disease and renal outcomes.European Heart Journal.2022.https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehac352/6652163?redirectedFrom=fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1238464, encodeId=180d1238464b6, content=q, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 13 12:48:07 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357961, encodeId=f43b135e96158, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379273, encodeId=56ef13e9273e7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428701, encodeId=886c1428e013e, content=<a href='/topic/show?id=71b182e3237' target=_blank style='color:#2F92EE;'>#肾脏结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82732, encryptionId=71b182e3237, topicName=肾脏结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76614125796, createdName=szhvet, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563646, encodeId=f25d1563646d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
    2022-08-13 cyfguvgi

    q

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1238464, encodeId=180d1238464b6, content=q, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 13 12:48:07 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357961, encodeId=f43b135e96158, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379273, encodeId=56ef13e9273e7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428701, encodeId=886c1428e013e, content=<a href='/topic/show?id=71b182e3237' target=_blank style='color:#2F92EE;'>#肾脏结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82732, encryptionId=71b182e3237, topicName=肾脏结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76614125796, createdName=szhvet, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563646, encodeId=f25d1563646d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
    2022-08-11 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1238464, encodeId=180d1238464b6, content=q, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 13 12:48:07 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357961, encodeId=f43b135e96158, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379273, encodeId=56ef13e9273e7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428701, encodeId=886c1428e013e, content=<a href='/topic/show?id=71b182e3237' target=_blank style='color:#2F92EE;'>#肾脏结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82732, encryptionId=71b182e3237, topicName=肾脏结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76614125796, createdName=szhvet, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563646, encodeId=f25d1563646d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
    2022-08-11 cmsvly
  4. [GetPortalCommentsPageByObjectIdResponse(id=1238464, encodeId=180d1238464b6, content=q, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 13 12:48:07 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357961, encodeId=f43b135e96158, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379273, encodeId=56ef13e9273e7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428701, encodeId=886c1428e013e, content=<a href='/topic/show?id=71b182e3237' target=_blank style='color:#2F92EE;'>#肾脏结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82732, encryptionId=71b182e3237, topicName=肾脏结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76614125796, createdName=szhvet, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563646, encodeId=f25d1563646d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1238464, encodeId=180d1238464b6, content=q, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Sat Aug 13 12:48:07 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357961, encodeId=f43b135e96158, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379273, encodeId=56ef13e9273e7, content=<a href='/topic/show?id=ac549564240' target=_blank style='color:#2F92EE;'>#醛固酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95642, encryptionId=ac549564240, topicName=醛固酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428701, encodeId=886c1428e013e, content=<a href='/topic/show?id=71b182e3237' target=_blank style='color:#2F92EE;'>#肾脏结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82732, encryptionId=71b182e3237, topicName=肾脏结局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76614125796, createdName=szhvet, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563646, encodeId=f25d1563646d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 11 11:27:42 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
    2022-08-11 slcumt

相关资讯

JAMA Intern Med:口服Daprodustat方案治疗慢性肾病贫血

Daprodustat对慢性肾病贫血患者的治疗效果与阿法达贝泊相当,是一种有效地口服促红细胞生成治疗方案。

J RENAL NUTR:超市货架上的含磷食品有哪些?慢性肾病患者饮食“窘境”何日能破解?

为了在全球范围内进行CKD管理,迫切需要更多关于P添加剂的可见信息,以及在食品包装上精确标注。

拜耳CKD药物Kerendia获得欧盟批准

拜耳近日宣布,欧盟监管机构已批准 Kerendia (finerenone) 用于治疗患有与 2 型糖尿病相关的慢性肾病(CKD)的成年患者。

 Eur J Nucl Med Mol Imaging :[68 Ga]Ga-FAPI摄取与慢性肾病的状态相关

[68Ga]Ga-FAPI具有评估和量化CKD分级的潜力,而[68Ga]Ga-DOTATOC或[68Ga]Ga-PSMA摄入与肾功能无关。

Nrf2 激活剂 bardoxolone 治疗慢性肾病(CKD),FDA持反对意见

FDA 得出的结论是,提交的数据未能表明 bardoxolone 可有效减缓 Alport 综合征患者的肾功能丧失。

J RENAL NUTR:慢性肾病患者身体机能每况愈下?胃肠道症状多?可能你的营养已严重透支!

患者报告的身体功能较低、胃肠道症状较多以及目前吸烟与营养状况下降有关。

Baidu
map
Baidu
map
Baidu
map